Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Gynecol Oncol. 2021 May 25;162(2):345–352. doi: 10.1016/j.ygyno.2021.05.015

Figure 2:

Figure 2:

Disease-specific survival (DSS) for high-grade serous ovarian cancers (HGSOCs) by group (Group 1 includes patients who had a single site of recurrence and were ≥2 years out from secondary cytoreduction. Group 2 includes all other patients).